Abstract: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used to purge an ex vivo hematopoietic stem cell culture of cancer cells for engraftment in a mammal by administering the composition to the ex vivo hematopoietic stem cell culture in an effective amount.

Abstract: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used in the manufacture of a medicament for the treatment of a blood cancer in a mammal by administering the medicament in a therapeutically effective amount.

Abstract: Compositions comprising a peptide consisting of an amino acid sequence derived from a P2G-substituted SDF-1 protein are taught. The amino acid sequence consists of a first sequence consisting of 8 to 17 amino acids from the N-terminal portion of the SDF-1 protein and having a conserved KGVS motif. The amino acid sequences may also consist of one or more optional components selected from the group consisting of a second sequence consisting of 8 to 17 amino acids from the N-terminal portion of the SDF-1 protein and having a conserved KGVS motif, wherein the second sequence is covalently joined to the first sequence with or without a linker; and, a third sequence consisting of LKWIQEYLEKALN, or conservative substitutions thereof, wherein the third sequence is covalently joined to the first sequence with the linker. Methods of increasing multiplication of hematopoietic cells and enhancing proliferation of hematopoietic cells during engraftment are also taught.

Abstract: In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.